Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Commercial Sponsor
Hoffmann-La Roche
Summary
Eligible patients will be assigned to an experimental treatment cohort according to their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.